Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-IGR-28-10-2016-14:22:46:181-287 - samples

ABSTRACT: Whole-exome sequencing (WES) of 216 breast cancer metastasis-normal pairs from patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA or MOSCATO prospective trials (France).

PROVIDER: EGAD00001002747 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

Lefebvre Celine C Bachelot Thomas T Filleron Thomas T Pedrero Marion M Campone Mario M Soria Jean-Charles JC Massard Christophe C Lévy Christelle C Arnedos Monica M Lacroix-Triki Magali M Garrabey Julie J Boursin Yannick Y Deloger Marc M Fu Yu Y Commo Frédéric F Scott Véronique V Lacroix Ludovic L Dieci Maria Vittoria MV Kamal Maud M Diéras Véronique V Gonçalves Anthony A Ferrerro Jean-Marc JM Romieu Gilles G Vanlemmens Laurence L Mouret Reynier Marie-Ange MA Théry Jean-Christophe JC Le Du Fanny F Guiu Séverine S Dalenc Florence F Clapisson Gilles G Bonnefoi Hervé H Jimenez Marta M Le Tourneau Christophe C André Fabrice F

PLoS medicine 20161227 12

<h4>Background</h4>Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing.<h4>Methods and findings</h4>Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context ...[more]

PMID: 28027327

Similar Datasets

Whole-exome sequencing of breast cancer metastasis and corresponding blood samples

Project description:This study included samples from metastatic breast cancer patients who underwent a biopsy in the context of SAFIR01 (NCT01414933), SAFIR02 (NCT02299999), SHIVA (NCT01771458) and MOSCATO (NCT01566019) prospective trials. These French multicentre trials used high throughput genome analysis on fresh frozen tumor biopsies as a therapeutic decision tool for metastatic cancer patients, with solid cancers (SHIVA, MOSCATO) or specifically with breast cancer (SAFIR01, SAFIR02). All patients gave their informed consent for translational research and genetic analyses of their somatic DNA. Overall, whole-exome sequencing for a total of 216 pairs of metastatic tumor and unmutated DNA derived from corresponding blood samples was performed using Illumina technology. The results of the analysis of the mutational profile of metastatic breast cancer was reported in Lefebvre et al. (PMID:28027327).

| EGAS00001001695 | EGA

C. elegans LIN-28 controls temporal cell fate progression by regulating LIN-46 expression via the 5' UTR of lin-46 mRNA.

Project description: Not available

| S-EPMC8445076 | biostudies-literature

Bottom-up proteomics of FFPE tissue section from DLBCL patients

Project description:FFPE tissue sections of lymphoma patients were analyzed. All patients were enrolled in prospective multicenter DSHNHL clinical trials. The study included DLBCL samples from 357 patients.

2025-09-06 | PXD058736 | Pride

Transcription profiling of human samples from multiple myeloma patients treated with bortezomib or dexamethasone

Project description:The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Bone marrow aspirates were subject to a negative-selection procedure to enrich for tumor cells, and these samples were used for gene expression profiling using DNA microarrays. Data quality and correlations with trial outcomes were assessed by multiple groups. Gene expression in this dataset was consistent with data published from a single-center study of newly diagnosed multiple myeloma. Response and survival classifiers were developed and shown to be significantly associated with outcome via testing on independent data. The survival classifier improved on the risk stratification provided by the International Staging System. Predictive models and biologic correlates of response show some specificity for bortezomib rather than dexamethasone. Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents. Experiment Overall Design: Purified myeloma samples were collected prior to enrolment in clinical trials of bortezomib (PS-341). Samples were subject to replicate gene expression profiling using the Affymetrix 133A/B microarray. Data was normalized in MAS5.0 and the median of replicates is reported. Data was normalized to a Ttimmed mean of 15o and is NOT log transformed. Various patient parameters are reported as well as response, TTP and survival upon treatment with bortezomib or dexamethasone.

2008-06-17 | E-GEOD-9782 | biostudies-arrayexpress

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Project description:The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Bone marrow aspirates were subject to a negative-selection procedure to enrich for tumor cells, and these samples were used for gene expression profiling using DNA microarrays. Data quality and correlations with trial outcomes were assessed by multiple groups. Gene expression in this dataset was consistent with data published from a single-center study of newly diagnosed multiple myeloma. Response and survival classifiers were developed and shown to be significantly associated with outcome via testing on independent data. The survival classifier improved on the risk stratification provided by the International Staging System. Predictive models and biologic correlates of response show some specificity for bortezomib rather than dexamethasone. Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents. Keywords: Gene expression profiling; correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

2007-12-06 | GSE9782 | GEO

Gene expression profiling of melanoma cell lines (carrying NF1 loss-of-function) treated with DMSO (vehicle), MTX-216, MTX-211, trametinib, the combination of MTX-216 and trametinib, or pictilisib

Project description:In this study, we identified a multi-kinase inhibitor MTX-216 to be efficacious in blocking NF1 loss-of-function melanoma cells. To identify the mechansisms of action of MTX-216, we treated NF1 loss-of-function melanoma cell lines with MTX-216, MTX-211 (the structural analogue of MTX-216 that has no effect on melanoma cells) as well as commericial kinase inhibitors, trametinib and pictilisib, and compared their gene expression profiles.

2022-09-20 | GSE213588 | GEO

Enterobacter hormaechei strain:CM18-216 | isolate:CM18-216

Project description:Enterobacter hormaechei strain:CM18-216 | isolate:CM18-216 Genome sequencing

| PRJNA613546 | ENA

[HPP-2.0] Indentification of proteomic biomarkers for immunotherapy in esophageal cancer

Project description:We established a cohort of neoadjuvant immunotherapy for esophageal cancer, using proteomics to obtain protein molecules associated with efficacy and capable of characterizing the microenvironment of esophageal cancer and verify their effect in predicting immunotherapy response in an independent neoadjuvant immunotherapy cohort or in the real world. Future prospective clinical trials will be conducted to verify the effect of screening populations.

2024-02-26 | PXD050172 |

Effect of lin-28 and lin-46 on miRNA profile in late L1 stage Caenorhabditis elegans

Project description:Comparison of miRNA profiles of wildtype and lin-28(n719); lin-46(ma164) Caenorhabditis elegans nematodes at the L1 stage Two genotypes, wildtype vs. mutant. Biological replicates: 3 wild type, 3 mutant, independently grown and harvested. One replicate per slide.

2012-02-09 | E-GEOD-35634 | biostudies-arrayexpress

Homo sapiens

Project description:Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials

| PRJNA108377 | ENA